XBRANE Xbrane Biopharma AB (publ)

1.021USD10.35 SEK · STO-2.82%Mkt Cap: 21.03M USDP/E: —

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including…

Key Statistics

Company
Market Cap21.03M USD
Enterprise Value23.65M USD
Revenue (TTM)12.62M USD
Gross Profit8.83M USD
Net Income (TTM)12.55M USD
Revenue/Share0.61 USD
Last Price1.021 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees28
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0026598583
Valuation
P/E (Trailing)—
P/E (Forward)517.50
PEG—
EV/EBITDA-6.05
EV/Revenue1.87
P/S1.67
P/B0.40
EPS (TTM)-0.18 USD
EPS (Forward)0.0020 USD
52W Range
0.534634% of range1.972
52W High1.972 USD
52W Low0.5346 USD
Profitability
Gross Margin58.76%
Oper. Margin-28.36%
EBITDA Margin-30.97%
Profit Margin83.49%
ROE22.70%
ROA18.95%
ROIC-12.80%
ROCE-11.01%
Growth
Revenue Growth441.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.72M USD
CapEx (TTM)13.77M USD
FCF Margin-147.10%
FCF Yield-88.25%
Net Debt2.62M USD
Net Debt/EBITDA-0.67
Net Debt/FCF—
Balance Sheet
Debt/Equity0.10
Current Ratio3.21
Quick Ratio0.66
Book Value/Sh2.52 USD
Cash/Share0.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:125
Split DateOct 17, 2025
Analyst Consensus
Rating—
Target (Mean)1.676 USD
Upside (mean)+64.3%
Target Range1.676 USD – 1.676 USD
# Analysts1
Ownership
Shares Out.20.61M
Float17.36M
Insiders39.62%
Institutions9.28%
Technical
SMA 501.182 (-13.7%)
SMA 2000.9823 (+3.9%)
Beta0.70
S&P 52W Chg8.68%
Avg Vol (30d)164.89K
Avg Vol (10d)66.86K
Technical Indicators
RSI (14)40.2
MACD-0.4541
MACD Signal-0.1408
MACD Hist.-0.3133
BB Upper1.582 USD
BB Middle1.245 USD
BB Lower0.9072 USD
BB Width54.24%
ATR (14)0.1187 USD
Vol Ratio (20d)0.16x

About Xbrane Biopharma (STO: XBRANE)

›

Xbrane Biopharma (STO: XBRANE) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 28 employees.

The shares were at 10.35 SEK on 20 November 2026, up 2.7% over 52 weeks. Its 52-week range is 5.421 SEK to 20.00 SEK: the price is 48.2% below the high and 90.9% above the low.

Its market capitalisation is 213.27M SEK.

Xbrane Biopharma reports return on equity of 22.7%, an operating margin of -28.4% and revenue up 441.3% year over year.

Its debt exceeds its cash by 26.52M SEK, a debt-to-equity ratio of 0.10. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 17.00 SEK is 64.3% above the current price.